Healthlynked CORP 8-K filings

HealthLynked Corp. announces the appointment of George O'Leary as Interim CFO and the elimination of the COO position, alongside a planned $7.5 million financing.

HealthLynked Corp. issued a $5.7 million senior secured convertible note to a trust controlled by its CEO, consolidating prior debt and unpaid compensation.

HealthLynked Corp. announced key executive and board appointments, including a new COO and two directors, to bolster its strategic initiatives for national expansion and a Nasdaq uplisting.

HealthLynked Corp. completed a 1-for-100 reverse stock split to enhance market positioning, attract institutional investors, and prepare for potential uplisting.

HealthLynked Corp. issued a warrant to purchase 1,353,356 shares and extended the maturity dates of existing notes payable to a trust controlled by its CEO, Dr. Michael Dent.

HealthLynked Corp. released its Annual Shareholder Letter, emphasizing product development, strategic partnerships, and a vision for future growth driven by AI and telemedicine.

HealthLynked Corp. announces the appointment of Jeremy Daniel as its new Chief Financial Officer, effective January 15, 2025, replacing David Rosal, who resigned.

HealthLynked Corp. has entered into a financing agreement, issuing convertible notes and warrants to the Mary S. Dent Gifting Trust for a total of $900,000.

HealthLynked Corp. has promoted Bill Crupi to Chief Operating Officer, effective immediately, to enhance operational efficiencies and drive strategic initiatives.

HealthLynked Corp. has received a $1 million investment from its CEO, Dr. Michael Dent, to support the company's expansion and development of its healthcare services.

HealthLynked Corp. has appointed David Rosal as its new Chief Financial Officer, effective immediately, with a base salary of $150,000 per year.

HealthLynked Corp. reports the resignation of its Chief Financial Officer, George O'Leary, effective April 4, 2024, who will remain on the Board of Directors.